Insights
Search Results
Client Highlights
3.09.26
Wilson Sonsini Advises Lead Investor on SHINE’s $240 Million Equity Funding
On February 27, 2026, SHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding led by NantWorks founder Dr. Patrick Soon-Shiong, with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. Wilson Sonsini Goodrich & Rosati advised lead investor OZ Shine LLC—a new investment company led by Dr. Soon-Shiong—on the transaction.
Client Highlights
1.29.26
Wilson Sonsini Advises Think Bioscience on Patent Matters Related to Oversubscribed $55 Million Series A
On January 20, 2026, Think Bioscience (Think Bio), a Boulder-based biotechnology company focused on unlocking elusive drug targets, has raised $55 million in an oversubscribed Series A. The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures. Wilson Sonsini Goodrich & Rosati advised Think Bio on patent matters related to the transaction.
Client Highlights
1.03.25
Firm Advises Pleno on IP Diligence Related to $25 Million Series B
On December 12, 2024, Pleno, a clinical and multi-omics diagnostics company that is revolutionizing biological target detection, announced that it has closed $25 million in Series B funding from major investors Deerfield Management, Foresite Capital, and Medical Excellence Capital, among others. Wilson Sonsini Goodrich & Rosati advised Pleno on IP diligence related to the transaction.
Based in San Diego, California, Pleno is an early-stage start-up company developing the RAPTOR™ multi-omic instrument platform to enable a broad array of life science applications. The company makes complex multi-omic known-target detection accessible and affordable to everyone through the innovative use of its Hypercoding™ technology, which simplifies the entire process and enables unprecedented improvements in performance, cost, and scale.
The Wilson Sonsini team advising Pleno on IP diligence related to the Series B included Bill Barrett, Sara Patak, and Matt Garnica.
For more information, please see Pleno’s news release. Additional coverage is available in Fierce Biotech and the San Diego Business Journal.
Based in San Diego, California, Pleno is an early-stage start-up company developing the RAPTOR™ multi-omic instrument platform to enable a broad array of life science applications. The company makes complex multi-omic known-target detection accessible and affordable to everyone through the innovative use of its Hypercoding™ technology, which simplifies the entire process and enables unprecedented improvements in performance, cost, and scale.
The Wilson Sonsini team advising Pleno on IP diligence related to the Series B included Bill Barrett, Sara Patak, and Matt Garnica.
For more information, please see Pleno’s news release. Additional coverage is available in Fierce Biotech and the San Diego Business Journal.
Press Releases
11.15.24
Wilson Sonsini Goodrich & Rosati Elects 16 New Partners
Contact:
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Client Highlights
8.09.24
Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia
On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Client Highlights
3.20.24
Wilson Sonsini Advises Tempo Therapeutics on $12 Million Series A
On March 19, 2024, Tempo Therapeutics, a leading innovator in tissue engineering and regenerative medicine, announced the completion of a $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation (JJDC). Wilson Sonsini Goodrich & Rosati has represented Tempo Therapeutics since its inception as a spinout from UCLA and currently represents the company on all legal matters.
Client Highlights
4.17.23
Firm Advises on IP and Patent Matters for Merck’s $10.8 Billion Acquisition of Prometheus
On April 16, 2023, pharmaceutical company Merck announced the $10.8 billion acquisition of clinical-stage biotechnology company Prometheus in a deal that will boost Merck’s presence in immunology. Wilson Sonsini Goodrich & Rosati advised Prometheus on IP and patent matters related to the transaction.
Alerts
3.21.23
United States Imposes Export Restrictions on Beijing Genomics Institute (BGI) Group Subsidiaries over National Security Concerns
The U.S. Department of Commerce’s Bureau of Industry and Security (BIS) issued a final rule effective March 2, 2023, amending the Export Administration Regulations (EAR) by adding 37 entities to the Entity List, including certain subsidiaries of Beijing Genomics Institute (BGI) Group. BGI Group is among the world’s largest next generation sequencing (NGS) companies in the world. Consequently, a license would be required to export or reexport any goods, software, technology, or biological materials that are subject to the EAR with these listed BGI Group subsidiaries. Since most items are subject to a licensing policy of denial, the inability to share items subject to the EAR with the listed subsidiaries may provide a competitive advantage to companies developing competing NGS technologies.
Alerts
3.13.23
Federal Circuit Affirms Jazz Pharmaceutical's Risk Evaluation and Mitigation Strategy Patent Is Not Listable in Orange Book
On February 24, 2023, the Federal Circuit held that Jazz Pharmaceuticals, Inc. (Jazz) must delist U.S. Patent No. 8,731,963 (the ’963 Patent) from the U.S. Food and Drug Administration’s (FDA’s) “Orange Book” because the claims in the ’963 Patent to a method of Risk Evaluation and Mitigation Strategies (REMS) to control access of Jazz’s Xyrem® did not qualify as “a method of using [the] drug for which approval is sought” under 21 U.S.C. § 355(b). Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC, 60 F.4th 1373 (Fed. Cir. 2023).
Client Highlights
1.09.23
Wilson Sonsini Advises Arpeggio Biosciences on IP Matters Related to $17 Million Series A
On September 7, 2022, Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, announced a $17 million Series A funding round, following a $3.2 million seed round completed in 2020. Funding was led by Builders VC and will support ongoing development of Arpeggio’s drug pipeline, as well as its transcription-monitoring technologies. This Series A funding was also supported by Arpeggio’s seed round investors Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, with new participation from Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai (BoxOne Ventures), and Matthew De Silva (Longtail Capital). Wilson Sonsini Goodrich & Rosati represented Arpeggio in the transaction and advises the company on ongoing patent, regulatory, and business advisory matters.
Client Highlights
12.09.22
Wilson Sonsini Advises Prometheus Biosciences on IP Matters Related to $500 Million Offering
On December 8, 2022, Prometheus Biosciences, Inc. a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share. All of the shares to be sold in the offering are to be sold by Prometheus. The gross proceeds to Prometheus from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. The offering is expected to close on or about December 13, 2022, subject to the satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 681,818 shares of common stock. Prometheus intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and short-term investments, to fund the development of PRA023, PRA052, and its other research and development programs and for working capital and general corporate purposes.